NCT02096081View on ClinicalTrials.gov

The Treatment of Glabellar Frown Lines

PHASE4CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

November 30, 2014

Conditions
Glabellar Frown Lines
Interventions
DRUG

IncobotulinumtoxinA

20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection

DRUG

OnabotulinumtoxinA

20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection

Trial Locations (10)

10065

Merz Investigative Site #001297, New York

20005

Merz Investigative Site #001298, Washington D.C.

20037

Merz Investigative Site #001170, Washington D.C.

33146

Merz Investigative Site #001101, Coral Gables

37215

Merz Investigative Site #001097, Nashville

70006

Merz Investigative Site #001105, Metairie

90069

Merz Investigative Site #001099, Los Angeles

90404

Merz Investigative Site #001299, Santa Monica

95819

Merz Investigative Site #001300, Sacramento

02467

Merz Investigative Site #001098, Chestnut Hill

All Listed Sponsors
lead

Merz North America, Inc.

INDUSTRY

NCT02096081 - The Treatment of Glabellar Frown Lines | Biotech Hunter | Biotech Hunter